Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Prostate Cancer and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3687
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Prostate Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Prostate Cancer and Peptides.

    To find out more about Triple Analysis: Melanoma, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
AEgera
AEterna Zentaris
Affymax
Agenus
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
BioNetWorks
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Chiasma
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Colby
Compugen
Cosmo Bioscience
Cosmo Pharmaceuticals
CSL
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
ECI
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Flamel Technologies
Formula Pharmaceuticals
Galena Biopharma
Gemin X Pharmaceuticals
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Got-a-Gene
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karo Bio
Karyon-CTT
Kiadis
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
Nidus Laboratories
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
NPS Pharmaceuticals
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Pacific Biotech
Paladin Labs
Pantarhei Bioscience
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sapphire Therapeutics
Sarepta Therapeutics
Sareum
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Sophiris Bio
Spectrum Pharmaceuticals
Spirogen
SRI International
Sunesis
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tokai Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Twinstrand Therapeutics
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
WntResearch
Xerion
Xigen
Xoma
YM BioSciences
York Pharma
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEB071
AEZS-108
afamelanotide
afatinib
aflibercept
agatolimod
aldesleukin
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
angiopep+paclitaxel
APC-100
APO-866
APR-246
ARC-100
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
bafetinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bicalutamide
BMS-663513
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
Buparlisib
buserelin
Cabozantinib
carlumab
CB-10-01
CBP-501
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
corticorelin acetate
cositecan
CT-011
custirsen
danusertib
dasatinib
DCVax-prostate
decitabine
degarelix
denenicokin
denileukin diftitox
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E7449
EMD-273063
emepepimut-S
endostatin
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
Exherin
figitumumab
flutamide
FPI-01
fresolimumab
fulvestrant
ganetespib
ganitumab
gataparsen
GDC-0980
gefitinib
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
idronoxil
imatinib mesilate
imMucin
INCB-24360
inecalcitol
INSM-18
interferon
interleukin-12
interleukin-2
interleukins
intetumumab
IPH-1101
ipilimumab
IPP-204106
irosustat
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
KX2-391
L19-IL2
Lambrolizumab
lanreotide
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LGX818
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MDX-1379
MetXia
MGN-1601
MKC-1106-MT
MLN-8237
MORAb-004
Nab-docetaxel
nadroparin
NAFB001
netupitant
nilotinib
nilutamide
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
OGX-427
olaparib
olaratumab
OncoVAX
orteronel
OTS-102
ozarelix
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pasireotide
pasireotide LAR
peginterferon alfa-2b
perifosine
pertuzumab
pimasertib
plitidepsin
PLX-3397
poly-ICLC
polyclonal antibody stimulator
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
romidepsin
romurtide
ruxolitinib
sagopilone
sargramostim
SB-939
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
sotatercept
sunitinib malate
Survivac
TAK-448
talminogene laherparepvec
tandutinib
tasquinimod
temsirolimus
Tenarad
tesetaxel
thalidomide
thymalfasin
TM-30339
TOK-001
toremifene citrate
trabedersen
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
vapreotide, immediate-release
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volociximab
VX-001
YM-155
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Prostate Cancer and Peptides.
    To find out more about Triple Analysis: Melanoma, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More